natgillin/translations-raw huggingface dataset:
hydration of the gel obtained by diluting it with water by a factor of 3 to 20; 
hidratiranje gela dobivenog razrijeđivanjem vodom od 3 do 20 puta,
the recovery of said antibody, or a divalent functional fragment thereof, thus produced starting from the culture medium or said cultured cells. 
Antitijelo ili njegov dvovalentni funkcionalni fragment iz patentnih zahtjeva 1 do 4, naznačeno time da je rečeno citotoksično sredstvo mitotički inhibitor.
The method of claim 6, wherein expressing the protein or the polypeptide in the E. coli host cell is performed in the absence of exogenously added methionine to the culture medium or without a methionine feed. 
Postupak prema patentnom zahtjevu 5, naznačen time, da se eksprimiranje proteina ili polipeptida u bakterijskoj domaćinskoj stanici provodi u odsutnosti metionina egzogeno dodanog u medij za uzgoj ili bez prihranjivanja metioninom.
a receiver which receives a bitstream of an encoded video; an extractor which extracts, from the bitstream, information about a maximum size of a coding unit, which is a data unit in which an image is decoded, and split information indicating whether a coding unit of the image is split into coding units of a lower; 
- < ekstraktor (220) podešen tako, da iz toka bitova izvlači informaciju o maksimalnoj veličini kodirajuće jedinice, koja je jedinica podataka u kojoj je kodirana slika, informaciju o maksimalnoj dubini, koja označava ukupni broj mogućih dijeljenja maksimalne kodirajuće jedinice i informaciju o dubini kodiranja i načinu kodiranja jedinica slike;
borate at a concentration of 0.4 to 2.0 w/v%; and a sparingly soluble particulate compound, said compound having a solubility in water at 25°C of 0.001 to 0.1 w/v% and a particle size of 50 to 700 nm, and wherein said sparingly soluble particulate compound is nepafenac at a concentration of 0.25 to 0.35 w/v%. 
borat s koncentracijom od 0,4 do 2,0 % (masa/volumen); i teško topivi spoj lebdećih čestica, gdje navedenom spoju topivost u vodi na 25°C, iznosi od 0,001 do 0,1 % (masa/volumen).
A pharmaceutical composition comprising a compound of any one of claims 1-2, or a tautomer thereof, or a stereoisomer of said compound or said tautomer, or a pharmaceutically acceptable salt thereof, together with at least one additional therapeutic agent, and a pharmaceutically acceptable carrier or diluent. 
Farmaceutska smjesa, naznačena time, što sadrži najmanje jedan spoj iz bilo kojeg od zahtjeva 1-11, ili njegov tautomer, ili farmaceutski prihvatljivu sol spomenutog spoja ili spomenutog tautomera i farmaceutski prihvatljivi nosač ili razblaživač.
A powdery composition comprising a steroidal molecule; and a pharmaceutically acceptable carrier having a specific surface area greater than 200 m2/g and at the most 1000 m2/g; wherein the steroidal molecule is dissolved in a solvent absorbed onto the surface of the pharmaceutically acceptable carrier and wherein the steroidal molecule is present in the solvent In a supersaturated concentration. 
Praškasti kompozit, naznačen time, da sadrži steroidnu molekulu; i amorfni silicijev dioksid koji ima specifičnu površinu od najmanje 250 m2/g; gdje je steroidna molekula otopljena u otapalu apsorbiranom na površinu amorfnog silicijevog dioksida i gdje je steroidna molekula prisutna u otapalu u superzasićenoj koncentraciji.
wherein R is hydrogen, and, optionally, converting Compound A into a pharmaceutically acceptable acid addition salt or into a compound of Formula I, wherein R is tritium by bombarding Compound A with tritium gas in the presence of a catalyst selected from iridium, ruthenium, rhodium and palladium containing complexes, in a solvent selected from dichloromethane, chlorobenzene, DMF and DMSO or mixtures thereof; 
ili spajanje spoja formule 4 [image] s prikladnim reagensima za fluorinaciju odabranim od kalijeva fluorida ili tetrabutilamonijevog fluorida, kako bi se stvorili spojevi formule I [image] pri čemu supstituent R je vodik, te ako je poželjno, pretvaranje dobivenog spoja u farmaceutski prihvatljive kiselinske adicijske soli ili u spojeve formule I pri čemu je R tricij,
Use of a fully human anti-VAP-1 antibody according to any one of claims 1 to 6 for the manufacture of a pharmaceutical composition for treating a VAP-1 mediated inflammatory disorder selected from the group consisting of arthritides and connective tissue diseases, inflammatory bowel diseases, dermatoses, multiple sclerosis, inflammatory neuropathy, inflammatory myopathy, acute disseminated encephalomyelitis, vasculitis of the central nervous system, Sjögrens syndrome, diabetes, systemic lupus erythematosus, asthma, inflammatory liver disease, Graves disease and thyroiditis. 
Uporaba potpuno ljudskog anti-VAP-1 protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 3 za proizvodnju farmaceutskog sastava za liječenje VAP-1 posredovanog upalnog poremećaja odabranog iz grupe koja se sastoji od artritisa i bolesti vezivnog tkiva, upalnih bolesti crijeva, dermatoze, multiple skleroze, upalne neuropatije, upalne miopatije, akutnog diseminiranog encefalomijelitisa, vaskulitisa središnjeg živčanog sustava, Sjögrenovog sindroma, dijabetesa, sustavnog eritemskog lupusa, astme, upalne bolesti jetre, Gravesove bolesti i tiroiditisa.
A process for the synthesis of a compound according to claim 1, in which the process comprises a process for the synthesis of an acid salt of N-methylcyclopentylamine, the process comprising the reaction of cyclopentylamine with a chloroformate or di- tert -butyl carbonate, so as to form a cyclopentylcarbamate, followed by reduction of the cyclopentylcarbamate and acidification to the acid salt of N-methylcyclopentylamine. 
Postupak sinteze spoja u skladu s patentnim zahtjevom 1, naznačen time što se postupak sastoji u postupku sinteze kisele soli N-metilciklopentilamina, gdje postupak uključuje reakciju ciklopentilamina s klorformijatom ili di-tert-butil-karbonatom, kako bi se dobilo ciklopentilkarbamat, te redukciju ciklopentilkarbamata i zakiseljavanje do kisele soli N-metilciklopentilamina.
The present invention relates to a process using a serum-free medium for the growth and maintenance of mammalian cells in culture. 
Ovaj izum odnosi se na proces koji koristi medij bez seruma za uzgoj i održavanje stanica sisavaca u kulturi.
The process according to claim 1, wherein in the step (2), the reaction mixture is separated, and the organic phase is neutralized or acidified with the acid. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je u koraku (2) reakcijska smjesa razdvojena a organska faza je neutralizirana ili zakiseljena kiselinom.
is selected from N and CR7; wherein R7 is selected from hydrogen and C1-4alkyl; 
Y, je odabran od N i CR; pri čemu je R; odabran od vodika 1 C,ualkila;
While an acrolein acetal is formed in FIG. 35, it should be appreciated that other groups may be substituted for R13 and R14 of Scheme 9, such as those defined for the R8 and R9 groups exemplified in FIG. 
Dok je akrolein acetal formiran na slici 35, trebalo bi uvažiti da druge skupine mogu biti supstituirane na Ris i Rua iz sheme 9, tako kao što su definirane za Rg i Ro skupine, navedene kao primjer na slici 9, ili druge.
Re-stimulation: Number of wells stimulated 
Broj međunarodne objave:
The reaction mixture was then allowed to warm to room temperature and it was stirred overnight. 
Reakcijska se smjesa potom ugrije na sobnu temperaturu i miješa preko noći.
If an embossing relief must extend outwardly in the outer part, then the part containing said relief might be countersunk prior to emboss so that the packaging can be stacked on each other though embossing is provided in the surface. 
Ako se gravirani reljef mora prostirati prema van u vanjski dio, tada onaj dio koji sadržava navedeni reljef može biti konusno izglodan prije graviranja tako da u pakiranju mogu biti stavljeni jedan na drugi, premda je na površini izvedeno graviranje.
the at least one active immunogenic component is selected from live attenuated canine adenovirus type 2 (CAV2), live attenuated canine parvovirus (CPV), and combinations thereof; or 
(b) sadrži živi atenuirani adenovirus pasa tipa 2 (CAV2) i živi atenuirani parvovirus pasa (CPV) ili
A method of claim 9, wherein the disease state is selected from a group consisting of: multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosis, inflammatory bowel disease, lung inflammation, thrombosis, brain infection/inflammation, meningitis and encephalitis. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se bolesno stanje bira iz skupine koju čine: multipla skleroza, psorijaza, reumatoidni artritis, sistemni eritematozni lupus, upalna bolest crijeva, upala pluća, tromboza, infekcija/fupala mozga, meningitis i encefalitis.
The method of claim 9, further comprising controllably transporting the first water vehicle during the underwater observation. The method of claim 9, further comprising: 
Metoda iz zahtjeva 9, koju nadalje čini kontrolirani prijevoz prvog plovila (100) tijekom podvodnog promatranja.
at least one needle in the lumen configured to assume a deployed position and a retracted position; 
Renalni denervacijski kateter prema zahtjevu 1, pri čemu se najmanje jedna igla (113) prostire prema van u radijalnom smjeru.
In yet other aspects, the IL-10 expression construct comprises at least one nuclear targeting sequence 5′ to the IL-10 coding sequence, and in some aspects, IL-10 expression construct comprises at least one nuclear targeting sequence 3′ to the IL-10 coding sequence. 
Sastav za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da ekspresijski konstrukt obuhvaća najmanje jednu sekvencu za ciljanje jezgre 5' prema sekvenci koja kodira IL-10.
Calcium mobilisation assay 
Pokus mobilizacije kalcija
A compound according to [1], a salt thereof or a hydrate of the foregoing, wherein R1 represents a group represented by the formula —NR11gR11h, wherein R11g represents hydrogen or methyl, and R11h represents n-propyl, n-butyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl or tetrahydropyran-4-yl, and R11h may be substituted with a substituent selected from Substituent Group F, wherein Substituent Group F consists of methyl, ethyl, n-propyl, acetyl, dimethylamino, diethylamino, azetidinyl, pyrrolidinyl and piperazinyl, where each group included in Substituent Group F may be substituted with methyl or dimethylamino. 
Spoj prema zahtjevu 1, njegova sol ili hidrat navedenog, naznačen time da R' predstavlja skupinu prikazanu sa formulom -NR''#R!'", pri čemu R''5 predstavlja vodik ili metil, te R'" predstavlja n-propil, n-butil, pirolidin-3-il, piperidin-3-il, piperidin-4-il ili tetrahidropiran-4-il, 1 R!''" može biti supstituiran sa supstituentom odabranim iz supstitucijske skupine F, pri čemu supstitucijska skupina F sadrži metil, etil, n-propil, acetil, dimetilamino, dietilamino, azetidinil, pirolidinil i piperazinil, gdje svaka skupina koja je uključena u supstitucijsku skupinu F može biti supstituirana sa metil ili dimetilamino.
In a further aspect of this invention a process is provided for introducing a substance into a vial comprising: providing a vial having a mouth opening closed by a closure of this invention, passing a hollow needle through the closure, introducing the substance into the vial via the needle, withdrawing the needle from the vial and closure, and sealing the small residual puncture hole in the closure by heat sealing, i.e. by heating the elastomer material of the closure adjacent the puncture site so that the material fuses, e.g. using a focused laser beam, then allowing the material to cool and set. 
U daljnjem aspektu ovog izuma predviđen je postupak za uvođenje tvari u bočicu, koji postupak sadržava: dobavljanje bočice koja ima ulazni otvor zatvoren zatvaračem iz ovog izuma, provođenje šuplje igle kroz zatvarač, uvođenje tvari u bočicu kroz iglu, izvlačenje igle iz bočice i iz zatvarača i nepropusno zatvaranje male preostale izbušene rupice u zatvaraču pomoću vrućeg nepropusnog zatvaranja, to jest zagrijavanjem elastomernog materijala zatvarača uz mjesto na kojemu se nalazi rupica, tako da se materijal rastopi, na primjer korištenjem fokusiranog laserskog snopa, i tada se omogući da se materijal ohladi i skruti.
the pharmaceutical composition is administered directly to the external adventitial surface of a surgically exposed vessel; or 
(iii) farmaceutski sastav je primijenjen direktno na vanjsku adventijalnu površinu kirurški izloženog krvnog suda; ili
In a fourth aspect, this invention is methods of preparing compounds of the first aspect of this invention. 
U četvrtom aspektu, ovaj izum su postupci dobivanja spojeva iz prvog aspekta ovog izuma.
The compound as recited in Claim 6 wherein said additional therapeutic agent is selected from the group consisting of benzodiazepines, and antipsychotics. 
Spoj za uporabu prema zahtjevu 6, naznačen time da se navedeno dodatno terapijsko sredstvo bira iz skupine koju čine benzodiazepini, te antipsihotici.
A method of producing a compound of claim 1, by use of following chemistry process: wherein R1, R2, R3. 
Metoda prirpave spoja iz patentog zahtjeva 1, naznačena time da se upotrebljavaju sljedeći kemijski postupci:
wherein the opening of each pair of vertical posts has a constant width; 
umetanje para susjednih jedara (106a, 106b) kroz otvor (420) svakog para okomitih nosača (404, 406);
or a physiologically acceptable salt or solvate thereof. 
O ili njegov fiziološki prihvatljiv solvat.
manifestly customizing the compound of formula (I) or the physiologically acceptable salt as medicament. 
(d) očigledno prilagođavanje spoja formule (I) ili fiziološki prihvatljive soli kao lijeka.
is selected from the group consisting of: hydrogen, 
R! je odabran iz skupine koju čine:
Typically the additional active compound (c) is selected from the group consisting of (a) PDE IV inhibitors and (b) cortiocosteroids. 
Kombinacija u skladu s patentnim zahtjevom 5, naznačena time, da je aktivni spoj (c) odabran iz skupine koja se sastoji od (1) PDE IV inhibitora i (b) kortikosteroida.
Oil spill containment A substance for cleaning water from oil, oil products, or metal ions, comprising an aqueous solution of an organic polymer, wherein the organic polymer includes polysaccharide microgels having a molecular mass of 20,000-200,000 Da and a particle size of 50-600 nm, wherein a concentration of the polysaccharide microgels ranges from 0.1 to 20 g/l. 
Upotreba vodene otopine polisaharidnih mikrogelova za pročišćavanje vode od lebdećih čestica nafte ili naftnih proizvoda, 1 opcionalno od metalnih iona, imajući koncentraciju mikrogelova od 0,1 do 20 g/l, naznačeno time da se koristi sposobnost polisaharida da budu adsorbirani na interfaznoj površini u obliku mikrogelova, naznačeno time da mikrogelovi imaju molekularnu masu od 20.000 do 200.000 Da i veličinu čestice od 50 do 600 nm, naznačeno time da je pH vrijednost otopine izmijenjena tako da izazove formiranje aglomerata, sačinjenih od spomenutih lebdećih čestica nafte ili naftnih poizvoda premazanih tankom polisaharidnom opnom.
A stable aqueous composition of matter comprising a protein and a polyoxyethylene (POE) sorbitan, wherein said POE sorbitan is present at a concentration of from about 150 ppm to 10,000 ppm, and wherein said composition is free of polysorbate. 
Stabilan predmetni vodeni pripravak, naznačen time, da obuhvaća protein i polioksietilen (POE) sorbitan, pri čemu je POE sorbitan prisutan u koncentraciji od otprilike 150 ppm do 10 000 ppm, te time, da spomenuti pripravak ne sadrži polisorbat.
is a nitrogen atom, or is a methine or 1-vinyl-2-ylidene group optionally substituted by a hydroxyl group, a lower alkyl group or a hydroxy-lower alkyl group; 
je atom dušika ili metin ili 1-vinil-2-iliden skupina po izboru supstituirana hidroksilnom skupinom, C1-6alkilnom skupinom ili hidroksi-C1-6alkilnom skupinom;
Conventional organic solvents known to persons skilled in the art may be used to produce the (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol solution, in particular alcohols such as methanol, ethanol, 1-propanol and 2-propanol, esters such as ethyl acetate, ketones such as acetone and ethylmethyl ketone, ethers such as diethyl ether, tert-butyl methyl ether, 1,4-dioxane and tetrahydrofuran, nitriles such as acetonitrile, chlorinated hydrocarbons such as dichloromethane, aromatic hydrocarbons such as toluene, and also dimethyl formamide and dimethyl sulfoxide. 
11. Postupak za pripremanje kristalne modifikacije B prema bilo kojem od zahtjeva 6-8 naznačen time da sadrži korak (a) taloženja (1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)fenola iz otopine, pri čemu je otapalo metanol, etanol, 1-propanol, 2-propanol, etil acetat, aceton, etil metil keton, dietil eter, tert-butil metil eter, 1,4-dioksan, tetrahidrofuran, acetonitril, diklorometan, toluen, dimetilformamid ili dimetil sulfoksid.
a length of from 8 base pairs (bp) to 30 bp; or a length of from 15 base pairs (bp) to 18 bp. 
(1i) duljinu od 8 parova baza (bp) do 30 bp; ili (ili) duljinu od 15 parovi baza (bp) do 15 bp.
The method of claim 1, wherein the CTLA4-Ig molecules of the composition are characterized by less than or equal to 4.0 area percent CTLA4-Ig high molecular weight species as determined by size exclusion chromatography and spectrophotometric detection. 
Pripravak prema zahtjevu 1, gdje su CTILA4-Ig molekule manje ili jednake 0.5 posto površine od vrsta visoke molekulske težine kako je određeno kromatografijom isključenja po veličini i spektrofotometrijskim otkrivanjem.
at least one fungicide selected from the group consisting of bixafen, fluxapyroxad, penflufen, isopyrazam, fluopyram, fenpyrazamine and sedaxane. 
(b) najmanje jedan fungicid odabran iz skupine koja se sastoji od biksafena, fluksapiroksada, penflufena, izopirazama, fluopirama, fenpirazamina i sedaksana.
The invention thus conceived is susceptible of numerous modifications and variations, as long as these are within the scope of the appended claims; moreover, all the details may be replaced with other technically equivalent elements, as long as these are within the scope of the claims. 
Takva koncepcija predmetnog izuma podložna je brojnim izmjenama i inačicama, a sve spadaju u opseg priloženih patentnih zahtjeva; štoviše, sve navedene pojedinosti mogu se zamijeniti drugim tehnički jednakovrijednim elementima.
A combination therapeutic means according to claim 20 which is suitable for administration to a human patient in need thereof, and which comprises as active ingredients: (i) an antibody or an antigen-binding fragment thereof according to any one of claims 1 to 12, a chimeric molecule according to claim 13, a chimeric antigen receptor according to claim 14, a cell according to claim 17 or a polynucleotide according to claim 15 or 16, and (ii) an additional immunotherapeutic agent, in particular an immunotherapeutic agent involving T cells, such as a T cell bearing a CAR molecule as defined in claim 13 or 14 or a CAR molecule targeting a cell receptor or antigen such as, CD19, CD20 CD52 or Her2. 
Kombinirano terapijsko sredstvo u skladu s patentnim zahtjevom 20 koje je pogodno za primjenu na humanom pacijentu kod koga postoji potreba za njim i koje sadrži aktivne sastojke: (i) antitijelo ili njegov antigen-vezujući fragment u skladu s bilo kojim od patentnih zahtjeva 1 do 12, himerna molekula u skladu s patentnim zahtjevom 13, himerni receptor antigena u skladu s patentnim zahtjevom 14, stanicu u skladu s patentnim zahtjevom 17 ili polinukleotid u skladu s patentnim zahtjevom 15 ili 16, i (di) dodatno imunoterapijsko sredstvo, naročito imunoterapijsko sredstvo koje uključuje T stanice, kao što je T stanica koja nosi CAR molekulu kao što je definirana u patentnom zahtjevu 13 ili 14 ili CAR molekula koji ciljno djeluje na stanični receptor ili antigen kao što je, CD19, CD20 CDS52 ili Her2.
11 shows a cross-sectional view of an open packaging comprising to sides 64 and 65 and a hinge part 66 . 
Slika 11 prikazuje pogled na poprečni presjek otvorenog pakiranja koje se sastoji od dvije strane 64 i 65 i od zglobnog dijela 66.
Combination of 5-FU & IFNa 
Kombinacija od 5-FU i IFNqa
For example, it could have either a volatile or non-volatile memory with look-up tables correlated to various application rates. 
Tako, na primjer, on može imati bilo nestalnu ili stalnu memoriju s tabelama za pretraživanje povezanim s različitim brzinama nanošenja.
The mouse of claim 1, wherein the endogenous mouse k light chain locus comprises 
Miš prema zahtjevu 1, naznačen time, što se alel endogenog mišjeg lakog 2 (lambda) lanca sastoji od:
X5-X8 are independently selected from the group consisting of N, C and S, wherein at least one X must be N or S; 
Xs5 do Xg su neovisno odabrani iz skupine koju čine N, C 1 S, pri čemu najmanje jedan X mora biti N ili S;
The process of claim 11, wherein said crystallized compound is in the form of spherical shaped agglomerates. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što je navedeni kristalizirani spoj u obliku kuglastih aglomerata.
6 shows the operating member of the tap head according to the invention in detail; 
6 pobliže prikazuje upravljački dio glave priključka u skladu sa izumom;
and the said analgesic is selected from aspirin, acetaminophen, phenacetin, fentanyl, sufentanil, methadone, acetyl methadol, buprenorphine, and morphine. 
i navedeni analgetik je izabran od aspirina, acetaminofena, fenacetina, fentanila, sufentanila, metadona, acetil metadola, buprenorfina i morfina.
Use of a compound of the formula [I] of claim 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof as an active ingredient for the production of a pharmaceutical agent capable of inhibiting undesirable cell proliferation. 
Upotreba spoja formule [I] u skladu s patentnim zahtjevom 24, ili njegove farmaceutski prihvatljive soli, naznačena time što je spoj formule [I] aktivni sastojak u proizvodnji farmaceutskog sredstva koje može inhibirati nepoželjnu staničnu proliferaciju.
A liquid pharmaceutical composition comprising: 
Tekući farmaceutski sastav, naznačen time, da obuhvaća
In accordance with a sixth aspect, the present invention is directed to use of a functional filler as defined in accordance with the first, second or third aspects of the present invention in a recycled polymer derived from at least one waste polymer, wherein the at least one waste polymer is cleaned, for example (solvent-free) dry cleaned, in accordance with the first, second or third aspects of the present invention. 
"oblogu, koja sadrži prvi spoj, koji sadrži krajnju propanskokiselinsku skupinu ili etilensku skupinu, uz jednu ili dvije susjedne karbonilne skupine; i miješanju potrošenog otpadnog polimera s funkcionalnim punilom kako bi se dobilo reciklirani polimer, gdje funkcionalno punilo dolazi u količini jednakoj ili većoj od 10%, težinski, otpadnog polimera.
The antibody which binds to human PD-1 of claim 6, wherein the heavy chain comprises amino acid residues 20 to 466 of SEQ ID NO: 31 and the light chain comprises amino acid residues 20 to 237 of SEQ ID NO: 36. 
Antitijelo prema patentnom zahtjevu 6, naznačeno time što teški lanac sadrži aminokiselinske ostatke 20 do 466 iz sekv. id. br.: 31 i lagani lanac sadrži aminokiselinske ostatke 20 do 237 iz sekv. id. br.: 36.